Alamar Biosciences, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2026. Unaudited results are presented against the comparable 2025 periods. Alamar is a commercial-stage proteomics company selling its NULISA platform, including ARGO HT instruments, consumables and services, primarily for research use. It completed its IPO in April 2026.
Financial performance
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Revenue | $33.5m | $19.9m | $89.0m | $49.2m |
| Gross profit | $20.6m | $11.9m | $52.8m | $26.9m |
| Gross margin | 61.5% | 59.7% | 59.3% | 54.6% |
| Operating expenses | $35.8m | $19.8m | $93.8m | $51.2m |
| Operating loss | $15.1m | $7.9m | $41.0m | $24.4m |
| Net loss | $13.3m | $8.0m | $47.9m | $22.7m |
| Net loss per share, basic and diluted | $0.19 | $0.69 | $1.02 | $1.99 |
Q3 product revenue was $26.3m, including $17.8m of consumables and $8.5m of instruments; service revenue was $7.2m. For the nine months, consumables revenue grew 122% to $47.3m, instrument revenue grew 52% to $23.6m, and services revenue grew 50% to $18.1m. Management attributed growth to a larger instrument base, higher demand for multiplex panels, higher consumable prices and increased TAP services.
At September 30, 2026, cash and cash equivalents were $121.5m and short-term investments were $105.1m, or $226.6m unrestricted liquidity; restricted cash was $4.9m. Current assets were $317.7m versus current liabilities of $33.5m. The company had no borrowings outstanding, with $54.0m available under its $60.0m SVB revolving facility after $6.0m of letters of credit. Term debt had been repaid in August. Nine-month operating cash use was $46.4m, investing cash use was $109.8m, and financing cash provided was $247.8m. The filing does not provide standalone Q3 cash-flow figures.
Changes and notable items
- Revenue increased 68% in Q3 and 81% for the nine-month period. Gross margin improved in both comparisons, primarily from a higher consumables mix, lower instrument costs and higher consumables prices.
- Operating expenses rose faster than revenue: Q3 R&D increased 58% and SG&A 105%. Management cited expanded product development and headcount, higher stock-based compensation, and increased legal and accounting costs.
- Nine-month net loss included a $10.0m noncash loss from remeasurement of convertible notes before their automatic conversion into common stock at the IPO. The IPO generated $197.8m net proceeds; the notes converted into 3.9m shares.
- Common shares outstanding were 69.5m as of October 31, 2026. The basic and diluted share counts rose substantially following the IPO and conversions, so per-share comparisons are affected by the changed share base.
Outlook, risks and contingencies
- Management expects 2026 full-year stock-based compensation expense of $13m–$15m and expects significant operating expenses and losses to continue as it invests in R&D, manufacturing and commercialization. It believes current unrestricted cash, cash equivalents and investments will fund current plans and anticipated obligations for at least 12 months; longer-term capital needs may require additional financing.
- Alamar intends to submit the ARGO HT/DX instrument to the FDA for marketing authorization in 2027. Current products are sold for research use only; clinical or diagnostic commercialization would require applicable regulatory authorization.
- Key disclosed risks include ongoing losses, reliance on research and academic funding, competition, variable and lengthy sales cycles, manufacturing scale and quality, single-source suppliers, tariffs and international operations, and regulatory and intellectual-property risks.
- Olink’s Delaware patent-infringement action concerning NULISA remains pending. Alamar’s motion to dismiss the amended complaint is pending; its appeal of the PTAB decision was dismissed on October 13, 2026. The company said a loss was not probable as of September 30 and that it could not reasonably estimate a possible loss.
- Operating lease liabilities totaled $42.4m; undiscounted future lease payments were $79.8m. The company also disclosed an ADDF research funding agreement of up to $10.0m, with a low-single-digit royalty on ARGO DX sales and potential sales milestone payments capped at $4.75m.
- Management reported disclosure controls and procedures were effective at the reasonable-assurance level and no material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Whether revenue and consumables demand continue to grow, and whether instrument placements translate into recurring consumables sales.
- Whether margin improvement persists as manufacturing capacity expands and inventory reserves, product mix, pricing and tariffs change.
- Cash-burn trends, the assumptions behind management’s at-least-12-month liquidity assessment, and any need for additional capital or dilution.
- Progress, timing and regulatory pathway for ARGO HT/DX, including the planned 2027 FDA submission.
- Developments in the Olink litigation and any resulting financial, operational or product implications.
- Customer exposure to research-funding reductions, supply constraints, manufacturing quality issues and single-source suppliers.